Amgen, Inc.

Vigil Neuroscience’s TREM2 agonist iluzanebart failed in a Phase II study for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and deadly neurod

When clinical trial details are teased but deferred, investors will take a steer from the company management and key opinion leader commentaries. This has the potential for bias. Recent events around

Data presented in two oral sessions at the American Society of Clinical Oncology on the PD-1 inhibitor Libtayo (cemiplimab-rwlc) and the BCMAxCD3-directed bispecific antibody linvoseltamab illustrate

Europe’s Unified Patent Court has given its first insight into how it will handle infringements of second medical use claims, after its verdict in the showdown between Sanofi/Regeneron Pharmaceuticals